Showing results (141-150 of 276) with videos related to
Sort By:
Pageof 28
Annals of Surgical Oncology|June 14, 2017
Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter StudyLucas Minig, Florian Heitz, David Cibula, et al.Cancers|January 11, 2022
Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer-Impact for Diagnosis and Treatment MonitoringElena Ioana Braicu, Andreas du Bois, Jalid Sehouli, et al.Annals of Surgical Oncology|August 3, 2018
Skeletal Muscle Attenuation (Sarcopenia) Predicts Reduced Overall Survival in Patients with Advanced Epithelial Ovarian Cancer Undergoing Primary Debulking SurgeryBeyhan Ataseven, Teresa González Luengo, Andreas du Bois, et al.Journal of Surgical Oncology|March 28, 2023
Treatment and survival of patients with malignant ovarian sex cord-stromal cell tumours: An analysis of the Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) study group CORSETT databaseMaximilian Klar, Helmut Plett, Philipp Harter, et al.Archives of Gynecology and Obstetrics|July 21, 2021
The effect of fertility-sparing surgery on sexuality and global quality of life in women with malignant ovarian germ cell and sex cord stromal tumors: an analysis of the CORSETT database of the AGO study groupAnnette Hasenburg, Hellmut Plett, Bernhard Krämer, et al.Annals of Surgical Oncology|September 30, 2006
Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trialPhilipp Harter, Andreas du Bois, Maik Hahmann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2023
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA StudyUrsula A Matulonis, Domenica Lorusso, Ana Oaknin, et al.Gynecologic Oncology|October 26, 2024
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summaryKathleen N Moore, Domenica Lorusso, Ana Oaknin, et al.The Lancet. Oncology|August 14, 2018
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialRadoslav Chekerov, Felix Hilpert, Sven Mahner, et al.Journal of the National Cancer Institute|January 26, 2015
Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 studySven Mahner, Julia Jueckstock, Felix Hilpert, et al.Pageof 28